Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q3 2020 Earnings Presentation
8 slides from Agilent Technologies's earnings presentation, September 2020
Slide 1: Agilent Technologies Q3'20 Results Presentation
Agilent Technologies Q3'20 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth opportunities, new pr
Slide 3: Agilent Results Q3'20
Agilent Results Q3'20 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q3'20 Financial Metrics Q3'20 Highlights • Revenues: $1.26B, -3.1% y/y core(1)(2), • Revenue: Growth in Food and Pharma markets was -1.0% y/y reported (+3.4% M&A, -1.3% FX). more than offset b
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Revenue performance continued to reflect the Instrumentation and Informatics for Analytical Laboratories impact of the global pandemic. A&G (helped by COVID spending on research) and Food grew. China grew HSD with broad performance across markets. • Bio
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) Analytical Laboratory • Core growth led by Pharma and Food markets. Consumables and Services All other markets saw declines, largely due to COVID-19 headwinds. Growth in Services offset LSD declines in Consumables. • Regionally, performance tracked with relative phasing
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) • Core revenue decline driven by ongoing softness in Pathology, Genomics, and A&G Research and declines in non-COVID Dx Nucleic Acid Manufacturing testing, especially in the US. • Announced plans to expand its NASD production facility in Frederick, CO. The expans
Slide 7: Q3'20 Results by End Market
Q3'20 Results by End Market Analytical Laboratory End Markets Chemical Q3'20 revenues: -2% y/y on core(2) basis & Energy 21% Pharma & Biotech: Up 2% versus a difficult compare as both Pharma & Biotech Small Molecule and Bio-Pharma grew LSD. Strength in NASD Food 35% and Mass Spec. 10% Academia
Slide 8: Agilent's Response to COVID-19
Agilent’s Response to COVID-19 “During this challenging time, Agilent's focus is on four key areas. The first is ensuring the health and safety of the Agilent team and their loved ones. Second, is our unwavering commitment to our customers. From the early stages of the pandemic, we took decisive act